Featured Research

from universities, journals, and other organizations

Cancer drug shows promise for treating scleroderma

Date:
March 28, 2011
Source:
Hospital for Special Surgery
Summary:
A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.

A drug approved to treat certain types of cancer has shown promising results in the treatment of patients with scleroderma, according to results from an open-label Phase II trial. While the drug's efficacy must be demonstrated in a Phase III trial, the gold standard for testing a drug, researchers are optimistic that Gleevec™ (imatinib) could potentially be a weapon against the chronic connective tissue disease for which a treatment has remained elusive.

"This trial showed Gleevec has acceptable safety and tolerability, and there are hints of efficacy or suggestions the drug may work," said Robert Spiera, M.D., an associate attending rheumatologist at Hospital for Special Surgery who led the study. "This study strongly suggests that a randomized placebo-controlled trial is warranted." The study appears Online First in advance of print in Annals of the Rheumatic Diseases.

To date, there has never been a drug that has been shown to be effective for scleroderma. For the study, investigators at Hospital for Special Surgery enrolled 30 patients with diffuse scleroderma, a widespread severe form of the disease, and gave them 400 mg of Gleevec per day. Patients were evaluated monthly for 12 months during treatment and were seen for follow-up three months after discontinuing the drug.

To measure the effectiveness of the drug, researchers used a tool known as the modified Rodnan skin score, a measure of how much skin is affected by the disease. "The skin score seems to be a very good marker of disease status and most scleroderma trials use this as an outcome measure," said Dr. Spiera. Investigators also measured lung function using tests for forced vital capacity (FVC), the maximum volume of air that a person can exhale after maximum inhalation, and diffusion capacity, a measurement of the lung's capacity to transfer gases. Lung disease is the main cause of mortality in scleroderma.

In the publication, researchers reported the final analysis of the Phase II trial data. Twenty-four of the patients completed 12 months of therapy. At one year, investigators saw a 22 percent improvement in skin scores and a 6.4 percent improvement in forced vital capacity scores. Diffusion capacity scores were stable. Dr. Spiera pointed out that in patients with scleroderma, lung function tests often get worse over time, so he was pleased with the results.

"I would be guarded to say that this drug works, because sometimes patients with scleroderma can get better on their own, especially if they have later disease, but our trial enrolled both patients with early and late disease and the early-stage disease patients also showed improvement," Dr. Spiera said. He said the findings of his open-label study need to be interpreted cautiously, and ultimately corroborated by evidence from a randomized, Phase III controlled trial.

The investigators suspected a longer duration of therapy would be necessary to see a benefit from the drug because it is an anti-fibrotic intervention, meaning it acts on the tissue, rather than an anti-inflammatory intervention, but the length of the therapy does limit the study's conclusions. "We recognize that some patients improve over time and the longer duration of therapy might have artificially led us to see a benefit that wasn't really from the drug," Dr. Spiera said. "That is always the criticism of any open-label trial in scleroderma, but you have to do an open-label trial before you can do a randomized trial." Still, he said, he was optimistic that the drug would show positive results in a Phase III trial.

The study is the largest single center trial of Gleevec in scleroderma to be reported with the longest duration of treatment and follow-up. Before this trial, test tube studies of human cells indicated that Gleevec might have some activity in combating the disease, and the drug was shown to be effective in a rodent model of the disease. Only anecdotal evidence, however, had been published on the drug's effectiveness in treating the disease in humans.

Dr. Spiera's study was funded primarily through the Rudolph Rupert Scleroderma Program at Hospital for Special Surgery. Novartis, the manufacturer of Gleevec, provided some monetary support and donated drug. The company was not involved in the design or analysis of the trial. Gleevec is approved in the United States for two types of cancer: chronic myeloid leukemia and gastrointestinal stromal tumor.

Systemic scleroderma affects not only the skin, but also underlying blood vessels, and often muscles and joints, as well as the gastrointestinal tract, kidneys, lungs and heart. According to the Scleroderma Foundation, roughly 300,000 individuals have scleroderma in the United States and roughly a third of these have the systemic kind. The disease typically strikes in the prime of patients' lives, when they are 30-50 years old.


Story Source:

The above story is based on materials provided by Hospital for Special Surgery. Note: Materials may be edited for content and length.


Journal Reference:

  1. R. F. Spiera, J. K. Gordon, J. N. Mersten, C. M. Magro, M. Mehta, H. F. Wildman, S. Kloiber, K. A. Kirou, S. Lyman, M. K. Crow. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Annals of the Rheumatic Diseases, 2011; DOI: 10.1136/ard.2010.143974

Cite This Page:

Hospital for Special Surgery. "Cancer drug shows promise for treating scleroderma." ScienceDaily. ScienceDaily, 28 March 2011. <www.sciencedaily.com/releases/2011/03/110328092457.htm>.
Hospital for Special Surgery. (2011, March 28). Cancer drug shows promise for treating scleroderma. ScienceDaily. Retrieved July 28, 2014 from www.sciencedaily.com/releases/2011/03/110328092457.htm
Hospital for Special Surgery. "Cancer drug shows promise for treating scleroderma." ScienceDaily. www.sciencedaily.com/releases/2011/03/110328092457.htm (accessed July 28, 2014).

Share This




More Health & Medicine News

Monday, July 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Traditional African Dishes Teach Healthy Eating

Traditional African Dishes Teach Healthy Eating

AP (July 28, 2014) Classes are being offered nationwide to encourage African Americans to learn about cooking fresh foods based on traditional African cuisine. The program is trying to combat obesity, heart disease and other ailments often linked to diet. (July 28) Video provided by AP
Powered by NewsLook.com
West Africa Gripped by Deadly Ebola Outbreak

West Africa Gripped by Deadly Ebola Outbreak

AFP (July 28, 2014) The worst-ever outbreak of the deadly Ebola epidemic grips west Africa, killing hundreds. Duration: 00:48 Video provided by AFP
Powered by NewsLook.com
Trees Could Save More Than 850 Lives Each Year

Trees Could Save More Than 850 Lives Each Year

Newsy (July 27, 2014) A national study conducted by the USDA Forest Service found that trees collectively save more than 850 lives on an annual basis. Video provided by Newsy
Powered by NewsLook.com
Google's Next Frontier: The Human Body

Google's Next Frontier: The Human Body

Newsy (July 27, 2014) Google is collecting genetic and molecular information to paint a picture of the perfectly healthy human. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins